Table 1 Baseline characteristics of participants according to quartiles of time-weighted cumulative AIP
Characteristics | Overall | Q1 (≤ − 0.50) | Q2 (− 0.50 to -0.12) | Q3 (− 0.12 to 0.28) | Q4 (≥ 0.28) | P value |
|---|---|---|---|---|---|---|
No. of participants | 54,440 | 13,610 | 13,610 | 13,610 | 13,610 | Â |
Age, year | 49.58 (41.87–56.57) | 49.82 (41.70–56.98) | 49.85 (42.06–56.95) | 49.71 (41.91–56.72) | 48.93 (41.81–55.52) |  < 0.0001 |
Male, n (%) | 41,652 (76.51) | 9388 (68.98) | 10,135 (74.47) | 10,798 (79.34) | 11,331 (83.25) |  < 0.0001 |
High school or above, n (%) | 4327 (7.95) | 1311 (9.63) | 1013 (7.44) | 937 (6.88) | 1066 (7.83) |  < 0.0001 |
Income > 800 RMB/month, n (%) | 8198 (15.06) | 2136 (15.69) | 2008 (14.75) | 1926 (14.15) | 2128 (15.64) | 0.001 |
Active physical activity, n (%) | 47,790 (87.78) | 12,091 (88.84) | 11,931 (87.66) | 11,908 (87.49) | 11,860 (87.14) | 0.0001 |
Current smoking, n (%) | 18,391 (33.78) | 4190 (30.79) | 4392 (32.27) | 4514 (33.17) | 5295 (38.91) |  < 0.0001 |
Current drinking, n (%) | 21,150 (38.85) | 5092 (37.41) | 4998 (36.72) | 5129 (37.69) | 5931 (43.58) |  < 0.0001 |
BMI, kg/m2 | 24.91 (22.66–27.25) | 23.12 (21.11–25.21) | 24.51 (22.41–26.76) | 25.40 (23.42–27.61) | 26.40 (24.46–28.44) |  < 0.0001 |
SBP, mmHg | 125.30 (115–140) | 120 (110–134) | 124 (113.30–140) | 129.30 (119.30–140) | 130 (120–141.30) |  < 0.0001 |
DBP, mmHg | 80 (76.70–90) | 80 (70.70–84.70) | 80 (75–90) | 80 (79.30–90) | 81.30 (80–90) |  < 0.0001 |
Hypertension, n (%) | 21,475 (39.45) | 3888 (28.57) | 5130 (37.69) | 6059 (44.52) | 6398 (47.01) |  < 0.0001 |
Hyperlipidemia, n (%) | 4456 (8.19) | 633 (4.65) | 935 (6.87) | 1265 (9.29) | 1623 (11.93) |  < 0.0001 |
Diabetes Mellitus, n (%) | 18,705 (34.36) | 1869 (13.73) | 2864 (21.04) | 4681 (34.39) | 9291 (68.27) |  < 0.0001 |
Antihypertensive drugs, n (%) | 5201 (9.55) | 829 (6.09) | 1153 (8.47) | 1457 (10.71) | 1762 (12.95) |  < 0.0001 |
Antidiabetic drugs, n (%) | 1128 (2.07) | 200 (1.47) | 254 (1.87) | 302 (2.22) | 372 (2.73) |  < 0.0001 |
Lipid-lowering drugs, n (%) | 486 (0.89) | 68 (0.50) | 116 (0.85) | 118 (0.87) | 184 (1.35) |  < 0.0001 |
FPG, mmol/L | 5.10 (4.64–5.66) | 4.92 (4.50–5.40) | 5.08 (4.63–5.60) | 5.12 (4.69–5.73) | 5.24 (4.76–5.90) |  < 0.0001 |
hs-CRP, mg/L | 0.78 (0.30–2.13) | 0.58 (0.20–1.72) | 0.72 (0.29–2.00) | 0.80 (0.31–2.20) | 1.00 (0.41–2.56) |  < 0.0001 |
eGFR, mL/min/1.73m2 | 82.7 (69.42–97.18) | 84.06 (71.56–97.51) | 82.75 (69.17–97.39) | 80.93 (67.44–96.38) | 82.92 (69.55–97.39) |  < 0.0001 |
TC, mmol/L | 4.90 (4.26–5.56) | 4.75 (4.19–5.38) | 4.89 (4.28–5.52) | 4.92 (4.25–5.60) | 5.04 (4.35–5.77) |  < 0.0001 |
LDL-C, mmol/L | 2.30 (1.77–2.79) | 2.11 (1.59–2.68) | 2.32 (1.85–2.80) | 2.40 (1.93–2.82) | 2.30 (1.76–2.80) |  < 0.0001 |